Noor Riyadh Mahmood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Noor Riyadh Mahmood has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ayad Kareem Khan
Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
2 shared publications - Mohammed Abdulaali Sahib
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq
1 shared publication - Mohammed Dheyaa Hamdi
Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
New series of Naproxen derivatives containing Azetidinone Moieties as Selective COX-2 inhibitors: Design, ADME study, molecular docking, molecular dynamic simulations in Baghdad, Iraq
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications, primarily for treating rheumatoid arthritis and other inflammatory conditions. They work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid into prostaglandins. Non-selective NSAIDs may lead to gastrointestinal side effects and kidney damage due to COX-1 inhibition, whereas selective COX-2 inhibitors provide anti-inflammatory benefits with fewer gastrointestinal risks. However, NSAIDs’ use is often restricted by their potential to cause erosions and ulcers in the gastrointestinal tract. A total of twelve novel Naproxen Derivatives with a 2-azetidinone ring have been proposed to evaluate their potential effectiveness against the cyclo-oxygenase-2-. Molecular docking was conducted with the crystalline structure of COX2 (code:1PXX), using GOLD software (CCDC) version 5.43, computer predictions were made, and the compounds were designed using ChemDraw version 22.2 (professional version). Subsequently, their selectivity with COX2 was assessed, with diclofenac selected as a control for comparison. In silico ADME studies were conducted, revealing the significant potential for binding, and drug-likeness was assessed using the Swiss ADME website. Additionally, Molecular dynamics simulations of compound A3 complexes with COX2 were performed using Schrödinger Suite 2023 software for 100 ns, estimating RMSD, RMSF, Ligand-Protein Contacts, and Ligand Torsion Profile results. Result showing the best binding energy within the receptor pocket, with a promising activity against the COX2 protein receptor. The highest PLP fitness levels were found in compounds A1 and A2 for anti-inflammatory protein (82.554 and 81.777, respectively, average value). All compounds were found to adhere to Lipinski’s rule of five, with high absorption from the gastrointestinal tract. Molecular dynamic results revealed that compound A3 had perfect alignment with the COX-2 receptor. In conclusion, these findings offer a promising direction for the development of effective treatments for inflammation.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessNew series of Naproxen derivatives containing Azetidinone Moieties as Selective COX-2 inhibitors: Design, ADME study, molecular docking, molecular dynamic simulations in Baghdad, Iraq
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications, primarily for treating rheumatoid arthritis and other inflammatory conditions. They work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid into prostaglandins. Non-selective NSAIDs may lead to gastrointestinal side effects and kidney damage due to COX-1 inhibition, whereas selective COX-2 inhibitors provide anti-inflammatory benefits with fewer gastrointestinal risks. However, NSAIDs’ use is often restricted by their potential to cause erosions and ulcers in the gastrointestinal tract. A total of twelve novel Naproxen Derivatives with a 2-azetidinone ring have been proposed to evaluate their potential effectiveness against the cyclo-oxygenase-2-. Molecular docking was conducted with the crystalline structure of COX2 (code:1PXX), using GOLD software (CCDC) version 5.43, computer predictions were made, and the compounds were designed using ChemDraw version 22.2 (professional version). Subsequently, their selectivity with COX2 was assessed, with diclofenac selected as a control for comparison. In silico ADME studies were conducted, revealing the significant potential for binding, and drug-likeness was assessed using the Swiss ADME website. Additionally, Molecular dynamics simulations of compound A3 complexes with COX2 were performed using Schrödinger Suite 2023 software for 100 ns, estimating RMSD, RMSF, Ligand-Protein Contacts, and Ligand Torsion Profile results. Result showing the best binding energy within the receptor pocket, with a promising activity against the COX2 protein receptor. The highest PLP fitness levels were found in compounds A1 and A2 for anti-inflammatory protein (82.554 and 81.777, respectively, average value). All compounds were found to adhere to Lipinski’s rule of five, with high absorption from the gastrointestinal tract. Molecular dynamic results revealed that compound A3 had perfect alignment with the COX-2 receptor. In conclusion, these findings offer a promising direction for the development of effective treatments for inflammation.
- Open Access
Design, In Silico, and Experimental Evaluation of Novel Naproxen–Azetidinone Hybrids as Selective COX-2 Inhibitors
The therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) is limited by gastrointestinal and renal adverse effects caused by non-selective COX-1 and COX-2 inhibition. To address this issue, a new series of naproxen–azetidinone hybrids was rationally designed and synthesized to enhance COX-2 selectivity and reduce off-target toxicity. The synthesis involved esterification, hydrazide formation, Schiff base condensation, and intramolecular cyclization with chloroacetyl chloride. Structural characterization was achieved through FT-IR, 1H NMR, and 13C NMR analyses. In silico ADMET profiling confirmed compliance with Lipinski’s rule and predicted favorable gastrointestinal absorption. Molecular docking revealed high COX-2 binding affinities (−11.93 to −9.72 kcal/mol), while MM/GBSA analysis identified compound N4c (ΔG = −62.27 kcal/mol) as the most stable complex, surpassing meloxicam and naproxen. DFT (B3LYP/6-31G(d,p)) frontier molecular orbital analysis indicated a narrow HOMO–LUMO gap (ΔE = 2.97 eV) for N4c, suggesting high electronic reactivity and strong enzyme interaction. Molecular dynamics simulations confirmed complex stability. In vivo anti-inflammatory testing using an egg-white-induced rat paw edema model showed that N4d, N4e, and N4f achieved higher inhibition (19.22%, 16.98%, and 16.98%) than naproxen (4.3%). These results highlight 2-azetidinone–naproxen hybrids as promising selective COX-2 inhibitors with enhanced pharmacokinetic and electronic properties.
Open AccessDesign, In Silico, and Experimental Evaluation of Novel Naproxen–Azetidinone Hybrids as Selective COX-2 Inhibitors
The therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) is limited by gastrointestinal and renal adverse effects caused by non-selective COX-1 and COX-2 inhibition. To address this issue, a new series of naproxen–azetidinone hybrids was rationally designed and synthesized to enhance COX-2 selectivity and reduce off-target toxicity. The synthesis involved esterification, hydrazide formation, Schiff base condensation, and intramolecular cyclization with chloroacetyl chloride. Structural characterization was achieved through FT-IR, 1H NMR, and 13C NMR analyses. In silico ADMET profiling confirmed compliance with Lipinski’s rule and predicted favorable gastrointestinal absorption. Molecular docking revealed high COX-2 binding affinities (−11.93 to −9.72 kcal/mol), while MM/GBSA analysis identified compound N4c (ΔG = −62.27 kcal/mol) as the most stable complex, surpassing meloxicam and naproxen. DFT (B3LYP/6-31G(d,p)) frontier molecular orbital analysis indicated a narrow HOMO–LUMO gap (ΔE = 2.97 eV) for N4c, suggesting high electronic reactivity and strong enzyme interaction. Molecular dynamics simulations confirmed complex stability. In vivo anti-inflammatory testing using an egg-white-induced rat paw edema model showed that N4d, N4e, and N4f achieved higher inhibition (19.22%, 16.98%, and 16.98%) than naproxen (4.3%). These results highlight 2-azetidinone–naproxen hybrids as promising selective COX-2 inhibitors with enhanced pharmacokinetic and electronic properties.